Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.20452/pamw.15909 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
This review aims to explore the potential of erythropoietin, a glycopeptide hormone, as a treatment option for Alzheimer's disease, which is the commonest cause of dementia. Despite years of focus and research, therapeutic options for Alzheimer's disease are not yet completely satisfactory. And as people age, they are likely to develop Alzheimer's Disease, further pressuring the healthcare system.
View Article and Find Full Text PDFErythropoietin: A Personal Alice in Wonderland Trip in the Shadow of the Giants.
Biomolecules
March 2024
Altius Institute for Biomedical Sciences, Seattle, WA 98121, USA.
The identification of the hormone erythropoietin (EPO), which regulates red blood cell production, and its development into a pharmaceutical-grade product to treat anemia has been not only a herculean task but it has also been the first of its kind. As with all the successes, it had "winners" and "losers", but its history is mostly told by the winners who, over the years, have published excellent scientific and divulgate summaries on the subject, some of which are cited in this review. In addition, "success" is also due to the superb and dedicated work of numerous "crew" members, who often are under-represented and under-recognized when the story is told and often have several "dark sides" that are not told in the polished context of most reviews, but which raised the need for the development of the current legislation on biotherapeutics.
View Article and Find Full Text PDFErythropoietin resistance-secondary to watermelon stomach: a forgotten story in chronic kidney disease patients.
Pan Afr Med J
April 2023
Department of General Practice and Family Medicine, General State Hospital of Nikaia, Nikaia, Greece.
Post-transplant erythrocytosis after kidney transplantation: A review.
World J Transplant
June 2021
Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin Madison, Madison, WI 53705, United States.
Post-transplant erythrocytosis (PTE) is defined as persistently elevated hemoglobin > 17 g/dL or hematocrit levels > 51% following kidney transplantation, independent of duration. It is a relatively common complication within 8 months to 24 months post-transplantation, occurring in 8%-15% of kidney transplant recipients. Established PTE risk factors include male gender, normal hemoglobin/hematocrit pre-transplant (suggestive of robust native kidney erythropoietin production), renal artery stenosis, patients with a well-functioning graft, and dialysis before transplantation.
View Article and Find Full Text PDFErythropoietin: a story of a discovery with Polish contribution.
Pol Arch Intern Med
March 2021
Department of Hematology, Jagiellonian University Medical College, Kraków, Poland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!